Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2015

Dietrich Martin Frederik, Yan Shirley Xiao, Schiller Joan Hoff

Abstract excerpt

Targeted therapy has become a valuable approach in adenocarcinoma of the lung. The number of actionable mutations has been continuously increasing with significant acceleration from discovery to clinical application. Herein, we present a case of innovative treatment using targeted therapy of a 75-year-old female with two primary adenocarcinomas of the lung. The first tumor was found to carry an activating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Molecular Targeted Therapy

Share to Neoplasms, Multiple Primary

Share to Proto-Oncogene Proteins c-met

Share to Pyrazoles

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 25902175
DOI: 10.1097/JTO.0000000000000448
PMCID: PMC4408888

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.PMID 25902175Read ↗

Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.Semantic proximity Read ↗

[Management of a patient with a double EGFR and MET anomaly by combined treatment].Semantic proximity Read ↗

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.Semantic proximity Read ↗

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.Semantic proximity Read ↗

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.Semantic proximity Read ↗

Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?Semantic proximity Read ↗

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.Semantic proximity Read ↗

MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.Semantic proximity Read ↗

A case treated with Crizotinib after secondary MET amplification of A double Rare L747S and G719S EGFR mutation Pulmonary Sarcomatoid Carcinoma.Semantic proximity Read ↗

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.Semantic proximity Read ↗

Carcinoma of unknown primary with a lung cancer profile in mediastinal and/or hilar lymph nodes: EGFR-mutant cases and a literature review of actionable drivers.Semantic proximity Read ↗

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.